US 12,479,922 B2
Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity
Ning Li, Jiangsu (CN); Guoqing Cao, Jiangsu (CN); Guojun Lang, Shanghai (CN); Chanjuan Liu, Shanghai (CN); and Yuhao Hu, Shanghai (CN)
Assigned to CYTOLYNX THERAPEUTICS HONG KONG LIMITED, Hong Kong (CN)
Appl. No. 17/766,371
Filed by CytoLynX Therapeutics Hong Kong Limited, Hong Kong (CN)
PCT Filed Sep. 25, 2020, PCT No. PCT/CN2020/117757
§ 371(c)(1), (2) Date Apr. 4, 2022,
PCT Pub. No. WO2021/068761, PCT Pub. Date Apr. 15, 2021.
Claims priority of application No. 201910960313.4 (CN), filed on Oct. 10, 2019.
Prior Publication US 2024/0052048 A1, Feb. 15, 2024
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01)] 11 Claims
 
1. An isolated monoclonal antibody targeting B cell maturation antigen (BCMA), wherein the antibody can bind to both human BCMA and monkey BCMA
wherein the antibody comprises a heavy chain variable region and a light chain variable region,
wherein the heavy chain variable region of the antibody comprises
a heavy chain complementarity determining region 1 (CDR-H1) comprising an amino acid sequence as set forth in SEQ ID NO: 1,
a heavy chain complementarity determining region 2 (CDR-H2) comprising an amino acid sequence as set forth in SEQ ID NO: 3, and
a heavy chain complementarity determining region 3 (CDR-H3) comprising an amino acid sequence as set forth in SEQ ID NO: 5; and,
wherein the light chain variable region of the antibody comprises:
a light chain complementarity determining region 1 (CDR-L1) comprising an amino acid sequence as set forth in SEQ ID NO: 7,
a light chain complementarity determining region 2 (CDR-L2) comprising an amino acid sequence as set forth in SEQ ID NO: 9, and
a light chain complementarity determining region 3 (CDR-L3) comprising an amino acid sequence as set forth in SEQ ID NO: 11.